// App-Quantinova.ai

Su1934 : LONG-TERM EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: 5-YEAR CUMULATIVE EXPOSURE OF GEMINI 1 COMPLETERS ROLLING INTO THE GEMINI OPEN-LABEL EXTENSION STUDY

Researchers

Presenter

  • Jean Frederic Colombel

Principal Investigators

  • Brian G. Feagan

  • Ira Shafran

  • Sharon -Byrne

  • Parnia Geransar

  • Alexandra James

  • Arpeat Kaviya

  • Javaria M. Khalid

  • Severine Vermeire

  • William J. Sandborn

  • Bruce E. Sands

  • Silvio Danese

  • Geert R. D'Haens

  • Arthur Kaser

  • Remo Panaccione

  • David T. Rubin

Medical Centers

  • Mayo Clinic Rochester, Rochester, Minnesota, United States

  • University of Calgary, Calgary, AB, Canada

  • Shafran Gastroenterology Center, Winter Park, Florida, United States

  • University of Chicago, Inflammatory Bowel Disease Center, Chicago, United States

  • University of California, San Francisco, San Francisco, California, United States

  • Humanitas University, Rozzano, Italy

  • University of Cambridge, Cambridge, United Kingdom

  • Robarts Research Institute, University of Western Ontario, London, Ontario, Canada

  • Icahn School of Medicine at Mount Sinai, New York, New York, United States

  • Academic Medical Center, Amsterdam, Netherlands

Locations

  • Canada

  • Italy

  • Netherlands

  • United Kingdom

  • United States

  • Belgium

Companies

  • Takeda Pharmaceutica

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

Outcome

  • Unknown

Study Design

  • open label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved